Estimating the Economic Impact of Sorafenib in Treatment of Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma (DTC) That is Refractory to Radioactive Iodine (RAI) Treatment
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.2200
https://www.valueinhealthjournal.com/article/S1098-3015(14)04130-8/fulltext
Title :
Estimating the Economic Impact of Sorafenib in Treatment of Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma (DTC) That is Refractory to Radioactive Iodine (RAI) Treatment
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04130-8&doi=10.1016/j.jval.2014.08.2200
First page :
A621
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1658